Abivax SA ADS/$ABVX

Abivax rises after presenting late-breaking Phase 3 ABTECT 8-week ulcerative colitis trial results showing obefazimod’s efficacy and safety.
4 hours agoLightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Abivax SA ADS

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Ticker

$ABVX
Sector
Primary listing

Employees

69
Headquarters

Abivax SA ADS Metrics

BasicAdvanced
$6.4B
-
-$3.62
0.13
-

Bulls say / Bears say

Obefazimod’s 50 mg once-daily dose achieved a placebo-adjusted clinical remission rate of 16.4% at week 8 in the pooled Phase 3 ABTECT-1 and ABTECT-2 trials, meeting the FDA’s primary and key secondary endpoints.
In July 2025, Abivax completed a $747.5 million public offering—including full exercise of the underwriters’ option—raising approximately $700.3 million in net proceeds and extending its cash runway into the fourth quarter of 2027.
The strong Phase 3 results have drawn significant analyst and acquisition interest; Leerink Partners raised its price target from $20 to $74 and cited potential M&A suitors including Merck, Roche, Pfizer, and Eli Lilly.
Abivax reported an operating loss of €93.7 million in the first half of 2025, up from €80.0 million in the same period of 2024, due mainly to €77.9 million in research and development expenses, reducing its cash balance to €60.9 million as of June 30, 2025.
Obefazimod’s regulatory path depends on results from the 44-week maintenance phase, expected in the second quarter of 2026; negative or delayed data could postpone the planned NDA submission in the second half of 2026, increasing risks to both valuation and approval timelines.
As a pure clinical-stage biotech, Abivax posted just $7.07 million in revenue over the last twelve months with a net loss of $229.46 million, highlighting its lack of marketed products and reliance on future pipeline success.
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ABVX

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs